Protiva Biotherapeutics

company

About

Protiva Biotherapeutics is a biotechnology company developing nucleic acid based pharmaceutical products.

  • 1 - 10

Details

Last Funding Type
Series C
Last Funding Money Raised
$4.95M
Industries
Biotechnology
Founded date
Jan 1, 2000
Number Of Employee
1 - 10
Operating Status
Close

Protiva Biotherapeutics, Inc., a development stage biotechnology company, develops nucleic acid based pharmaceutical products. The company focuses on developing products to fight various human diseases, such as cancer, influenza, Ebola, inflammatory diseases, and chronic viral infections. Its products include Pro 1, a tumor cell growth inhibitor, which kills tumor cells and inhibits tumor growth; Pro-101, an siRNA product that acts to inhibit the production of a protein involved in tumor growth; Pro-B, which acts to inhibit the expression of a protein, apolipoprotein B; Pro-EBOV and Pro-MARV that act to inhibit the replication of the Ebola and Marburg viruses; and Stable Nucleic-Acid Lipid Particle technology, an encapsulation and delivery system for nucleic acid payloads, such as short interfering RNA (siRNA), to target cells. The company also develops Hepatitis siRNA products for the treatment of hepatitis B and C. Protiva Biotherapeutics, Inc. has a research and development facility in Vancouver, Canada. The company was founded in 2000 and is based in Seattle, Washington. As of May 30, 2008, Protiva Biotherapeutics, Inc. operates as a subsidiary of Tekmira Pharmaceuticals Corp.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$8.25M
Protiva Biotherapeutics has raised a total of $8.25M in funding over 2 rounds. Their latest funding was raised on Jul 6, 2007 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 6, 2007 Series Unknown $3.30M 1 Detail
Jul 13, 2006 Series C $4.95M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Protiva Biotherapeutics is funded by 1 investors. Canadian Medical Discoveries Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Canadian Medical Discoveries Fund Series Unknown